|
|
1.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
|
2.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Allred DC, Anderson SJ, Costantino JP, Geyer CE Jr, Julian TB, Land SR, Mamounas EP, Nagtegaal ID, Paik S, Swain SM, Wickerham DL, Wolmark N
|
